Checklist for Prescribers:

Initiation of PrMINT-EMTRICITABINE/TENOFOVIR for Pre-exposure Prophylaxis (PrEP) in adults at high risk of HIV-1 infection

Individual Label

Instructions:

Complete checklist at each visit and file in individual's medical record.

I have completed the following prior to prescribing MINT-EMTRICITABINE/TENOFOVIR for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication:

LAB TESTS / EVALUATION

- ☐ Completed high risk evaluation of uninfected individual
- ☐ Confirmed a negative HIV-1 test immediately prior to initiating MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication
  - If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by Health Canada as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: MINT-EMTRICITABINE/ TENOFOVIR for a PrEP indication is contraindicated in individuals with unknown HIV-1 status or who are HIV-1 positive)
- ☐ Performed HBV screening test
- ☐ Confirmed estimated creatinine clearance (CrCl) ≥ 60 mL/min prior to initiation and periodically during treatment. In patients at risk for renal dysfunction, assess estimated CrCl, serum phosphorus, urine glucose and urine protein before initiation of MINT-EMTRICITABINE/TENOFOVIR and periodically while MINT-EMTRICITABINE/TENOFOVIR is being used. If a decrease in estimated CrCl is observed in uninfected individuals while using MINT-EMTRICITABINE/ TENOFOVIR for PrEP, evaluate potential causes and re-assess potential risks and benefits of continued use
- ☐ Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or HBV medications
- ☐ Evaluated risk/benefit for women who may be pregnant or may want to become pregnant

COUNSELING / FOLLOW-UP

- ☐ Discussed known safety risks with use of MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication
- ☐ Counseled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking MINT-EMTRICITABINE/TENOFOVIR for PrEP to reconfirm HIV-1-negative status
- ☐ Discussed the importance of discontinuing MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants
- ☐ Counseled on the importance of adherence to daily dosing schedule
- ☐ Counseled that MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication should be used only as part of a comprehensive prevention strategy
- ☐ Educated on practicing safer sex consistently and using condoms correctly
- ☐ Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)
- ☐ Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission
- ☐ Offered HBV vaccination as appropriate
- ☐ Provided education on where information about MINT-EMTRICITABINE/TENOFOVIR for a PrEP indication can be accessed
- ☐ Discussed potential adverse reactions
- ☐ Reviewed the MINT-EMTRICITABINE/TENOFOVIR Uninfected Individual Safety Brochure with the uninfected individual at high risk

MINT-EMTRICITABINE/TENOFOVIR is indicated in combination with safer sex practices for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults at high risk. Consult the product monograph at www.mintpharmaceuticals.com for contraindication, warnings, precautions, adverse reactions, interactions, dosing and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-877-398-9696.